ARCHIVES

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

This article is from The Cancer Letter archive.

Vol. 36 No. 33 | September 17, 2010

Download PDF Visit The Full Archive

Related Articles

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

IND-Exempt Trials May Need Special Review, HCFA Says.

September 29, 2000

NCI 1980s Challenge: Matching Schientific Priorities With Resources, DeVita Says At Swearing-In

August 15, 1980

Book For Survivors, Other New Publications

August 23, 1991

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992

Number Of Uninsured To Increase, Report Finds.

October 12, 2001